Olmesartan Medoxomil

Olmesartan medoxomil belongs to the class of drugs known as angiotensin II receptor blockers, or ARBs, which are among the most widely used treatments for hypertension ^[1][2]. Like other members of the class, it interrupts the renin-angiotensin-aldosterone system, the hormonal cascade that helps regulate blood pressure and fluid balance. Olmesartan itself is a nonpeptide molecule that competitively and selectively binds the angiotensin II type 1 receptor without meaningfully affecting the other receptors that govern the cardiovascular system ^[1].

The marketed substance is a prodrug. Olmesartan is poorly absorbed on its own, so it is formulated as olmesartan medoxomil, an ester that is rapidly and completely hydrolyzed to the active acid during absorption from the gut, after which no further conversion is needed ^[1]. Because the active form has a long duration of action, the drug provides blood-pressure control across a full 24-hour dosing interval when taken once daily ^[2].

The compound was discovered by the Japanese company Sankyo, later Daiichi Sankyo, and was patented in the early 1990s before entering clinical use in 2002; in several markets it has been co-promoted with Merck ^[2]. It is sold under brand names including Benicar in the United States and Olmetec elsewhere, and fixed-dose tablets pair it with the diuretic hydrochlorothiazide or with the calcium channel blocker amlodipine for patients who need more than one drug ^[2].

In clinical use olmesartan lowers blood pressure at least as effectively as older agents and compares favorably with several other ARBs in head-to-head trials, showing a relatively fast onset and a sustained 24-hour effect ^[1][2]. It is used both as a single agent and, when one drug is insufficient, in combination with a thiazide diuretic or a calcium channel blocker ^[2]. As with the ARB class generally, its blockade of angiotensin signaling has also drawn research interest in kidney protection and vascular health.

Olmesartan is a prescription-only medicine and is widely available as a generic. Its most distinctive safety concern is a rare but serious sprue-like enteropathy, first described in 2012, in which patients develop severe chronic diarrhea, weight loss, and intestinal changes resembling celiac disease that resolve after the drug is stopped ^[3]. Regulatory agencies in the United States and Europe have issued warnings about this reaction, and as a renin-angiotensin blocker olmesartan also carries the class contraindication in pregnancy because of the risk of fetal harm ^[2][3].

Olmesartan is prescription only and usually well tolerated. It can cause dizziness, headache, and, by its action on the kidney hormone system, a rise in potassium, so levels are sometimes checked. It can reduce kidney function in people with narrowed kidney arteries. A rare but characteristic problem is sprue-like enteropathy, a severe chronic diarrhea with weight loss that resolves when the drug is stopped. It must not be used in pregnancy because it can harm the fetus, and it should not be combined with aliskiren in people with diabetes or paired with ACE inhibitors. NSAIDs can blunt its effect and add kidney risk.

Olmesartan blocks the angiotensin II type 1 receptor, so it inherits the interactions of the class, plus one absorption problem of its own.

Colesevelam binds olmesartan in the gut. Taken at the same time it cut olmesartan exposure by 39% in healthy volunteers, an effect reduced but not abolished by separating the two by four hours.

Potassium-sparing diuretics, potassium supplements, salt substitutes and trimethoprim all add to the hyperkalemia that angiotensin blockade already promotes. Combining olmesartan with an ACE inhibitor or with aliskiren compounds hypotension, hyperkalemia and renal impairment without any offsetting benefit; aliskiren is contraindicated with olmesartan in diabetes. NSAIDs blunt the antihypertensive effect and, in elderly or volume-depleted people also taking a diuretic, can precipitate acute kidney injury.

Olmesartan raises serum lithium by altering proximal tubular handling, and lithium toxicity has been reported. Because olmesartan is hydrolysed to its active form during absorption and barely touches cytochrome P450, CYP-mediated interactions are not a feature.

Checking a whole stack? Run it through interactions + stacks.

Olmesartan medoxomil was discovered by the Japanese pharmaceutical company Sankyo, now Daiichi Sankyo, during the early 1990s effort to build on the success of the first angiotensin II receptor blocker, losartan. Chemists at Sankyo designed the molecule as a medoxomil ester prodrug so that an otherwise poorly absorbed acid could be taken orally and then cleaved in the intestinal wall to release the active olmesartan.

The compound was patented in the early 1990s and, after an extensive clinical program, received U.S. Food and Drug Administration approval in 2002, entering the market under the brand name Benicar in the United States and Olmetec in many other regions. It was subsequently co-developed and co-promoted with partner firms in several territories and became one of the most widely prescribed members of the ARB class. Fixed-dose combinations pairing it with hydrochlorothiazide and with the calcium channel blocker amlodipine followed in the years after launch, broadening its use in patients needing more than one agent.

Olmesartan earned a solid reputation as a potent, well tolerated once-daily antihypertensive, with head-to-head and network meta-analyses repeatedly placing it among the more effective ARBs for lowering both systolic and diastolic blood pressure. Because it acts at the receptor rather than on the angiotensin-converting enzyme, it spares patients the dry cough and angioedema risk that limit ACE inhibitors, a feature clinicians and patients value highly.

Its smooth 24-hour coverage from a single dose supports good adherence, and the drug is generally considered metabolically neutral. In fairness, olmesartan carries a recognized, if uncommon, association with a sprue-like enteropathy causing chronic diarrhea in a small number of long-term users, prompting an FDA label caution in 2013, and like all RAAS blockers it is contraindicated in pregnancy. On balance it remains a dependable, evidence-backed choice whose strengths are well documented.